Table 1.
Baseline characteristics of the patients (intention-to-treat population).
| Characteristic | Curcumin group (N = 10) | Matching placebo group (N = 10) |
|---|---|---|
| Age (years) | ||
| Median | 58 | 60 |
| Range | 22–85 | 38–85 |
| ECOG performance status score†, n (%) | ||
| 0 | 1 (10) | 1 (10) |
| 1 | 8 (80) | 9 (90) |
| 2 | 1 (10) | 0 (0) |
| Head and neck cancer stage, no. (%) | ||
| Locally advanced | 8 (80) | 9 (90) |
| Metastatic or recurrent | 2 (20) | 1 (10) |
| Head and neck cancer subgroup, no. (%) | ||
| Nasopharyngeal cancer | 1 (10) | 1 (10) |
| Squamous cell head and neck cancer | 9 (90) | 9 (90) |
| Comorbid disease‡, n (%) | 2 (20) | 1 (10) |
| Surgery, n (%) | 3 (30) | 2 (20) |
| Smoking, n (%) | 7 (70) | 8 (80) |
| Treatment | ||
| Concurrent chemoradiation, n (%) | 6 (60) | 8 (80) |
| Sequential chemoradiation, n (%) | 2 (20) | 0 (0) |
| Radiation only, n (%) | 0 (0) | 1 (10) |
| Palliative chemotherapy, n (%) | 2 (20) | 1 (10) |
| Mean daily calories intake ± SD (kcal/kg/day) | 27.5 ± 2.500 | 27.92 ± 2.465 |
†Eastern Cooperative Oncology Group (ECOG) performance status scores range from 0 to 5, with 0 indicating no symptoms, 1 indicating mild symptoms, and a higher number indicating increasing degrees of disability. ‡Comorbidity disease defined by metabolic diseases, diabetes, hypertension, or dyslipidemia.